Association Between Psychotic Experiences and Subsequent Suicidal Thoughts and Behaviors

Bromet, Evelyn J; Nock, Matthew K; Saha, Sukanta; Lim, Carmen C W; Aguilar-Gaxiola, Sergio; Al-Hamzawi, Ali; Alonso, Jordi; Borges, Guilherme; Bruffaerts, Ronny; Degenhardt, Louisa

Published in:
Jama psychiatry

DOI:
10.1001/jamapsychiatry.2017.2647

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2017

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 02-02-2020
IMPORTANCE  Community-based studies have linked psychotic experiences (PEs) with increased risks of suicidal thoughts and behaviors (STBs). However, it is not known if these associations vary across the life course or if mental disorders contribute to these associations.

OBJECTIVE  To examine the temporal association between PEs and subsequent STBs across the life span as well as the influence of mental disorders (antecedent to the STBs) on these associations.

DESIGN, SETTING, AND PARTICIPANTS  A total of 33 370 adult respondents across 19 countries from the World Health Organization World Mental Health Surveys were assessed for PEs, STBs (ie, ideation, plans, and attempts), and 21 DSM-IV mental disorders. Discrete-time survival analysis was used to investigate the associations of PEs with subsequent onset of STBs.

MAIN OUTCOMES AND MEASURES  Prevalence and frequency of STBs with PEs, and odds ratios and 95% CIs.

RESULTS  Of 33 370 included participants, among those with PEs (n = 2488), the lifetime prevalence (SE) of suicidal ideation, plans, and attempts was 28.5% (1.3), 10.8% (0.7), and 10.2% (0.7), respectively. Respondents with 1 or more PEs had 2-fold increased odds of subsequent STBs after adjusting for antecedent or intervening mental disorders (suicidal ideation: odds ratio, 2.2; 95% CI, 1.8-2.6; suicide plans: odds ratio, 2.1; 95% CI, 1.7-2.6; and suicide attempts: odds ratio, 1.9; 95% CI, 1.5-2.5). There were significant dose-response relationships of number of PE types with subsequent STBs that persisted after adjustment for mental disorders. Although PEs were significant predictors of subsequent STB onset across all life stages, associations were strongest in individuals 12 years and younger. After adjustment for antecedent mental disorders, the overall population attributable risk proportions for lifetime suicidal ideation, plans, and attempts associated with temporally prior PEs were 5.3%, 5.7%, and 4.8%, respectively.

CONCLUSIONS AND RELEVANCE  Psychotic experiences are associated with elevated odds of subsequent STBs across the life course that cannot be explained by antecedent mental disorders. These results highlight the importance of including information about PEs in screening instruments designed to predict STBs.
Prior studies suggest that psychotic experiences (PEs) are associated with an elevated risk of suicidal thoughts and behaviors (STBs). A 2016 meta-analysis by Honings et al\(^1\) based on 21 studies reported a 3-fold increased risk of STBs in people with PEs (odds ratio [OR], 3.2; 95% CI, 2.3-4.4). Other studies have documented a significant dose-response relationship between the number of PEs and increased odds of STBs.\(^2\)-\(^5\) Worryingly, prospective studies of school-aged children have reported strong associations between PEs and suicide attempts, with children with PEs having an approximately 11-fold increased odds of suicide attempts during the following 12 months (OR, 11.3; 95% CI, 4.4-28.6) compared with those without PEs.\(^6\)

Despite the growing body of evidence linking the presence of PEs with STBs, several research questions warrant closer attention. First, there is considerable variation in effect size estimates for these associations across studies, likely owing to differences in methods and analysis.\(^1\)-\(^7\),\(^8\) Thus, it would be informative to examine these associations across different sites using similar methods. Second, prior studies have documented that most common mental disorders are associated with increased odds of both PEs\(^9\) and STBs.\(^10\)-\(^12\) Third, although it has generally been assumed that mental disorders could increase the risk of each of 3 main STB outcomes (ie, ideation, plans, and attempts), recent studies have shown that only a subset of those with ideation also have suicide plans and attempts.\(^14\)-\(^16\) We examine the role of PEs with respect to the odds of transitioning between ideation, plans, and attempts. Fourth, there is evidence to suggest that the association between PEs and STBs may be stronger in samples based on children\(^6\) compared with estimates based on adult samples.\(^1\) Thus, it would be of interest to examine if the strength of the association between PEs and STBs differed across age groups within one study. If children and/or adolescents with PEs are differentially prone to STBs compared with older age groups, then this could have important clinical implications for screening in pediatric and adolescent settings.\(^5\) Fifth, there is considerable uncertainty about the population attributable risk proportions (PARPs) for STBs that are associated with PEs. For example, DeVylder et al\(^16\) reported that about 29% of suicide attempts were attributable to PEs among US adults. Kelleher et al\(^6\) have found that 56% to 75% of suicide attempts among adolescents aged 13 to 16 years were attributable to PEs (however, these estimates were imprecise; OR, 67.50; 95% CI, 11.41-399.21). Accurate and age-range specific estimates of these PARPs are important for policy-making and prevention purposes.

Specifically, we aimed to examine the association between PEs (and related PE type and frequency metrics) and subsequent STBs across the life span and the influence of mental disorders on these associations. We also examined the associations between PEs, suicide plans and attempts among individuals with suicidal ideation, and the PARPs of various STBs.

### Key Points

**Question** Are psychotic experiences associated with subsequent suicidal thoughts and behaviors (STBs), and do mental disorders (antecedent to the STBs) contribute to these associations?  

**Findings** Based on 33,370 adult survey respondents drawn from 19 countries, those with psychotic experiences had 2-fold increased odds of subsequent STBs (after adjusting for mental disorders). Psychotic experiences were predictors of subsequent STB onset across all life stages; however, the strength of the association was strongest in individuals 12 years and younger.

**Meaning** Screening for psychotic experiences may assist in the prediction of subsequent STBs.

### Method

#### Samples

The data were derived from 19 WHO World Mental Health (WMH) surveys, a coordinated set of community surveys administered in probability samples of adult respondents (18 years and older) in countries throughout the world.\(^1\) The weighted (by sample size) average response rate across the 19 surveys was 72.3%, with the highest response rate in Iraq (95.2%) and the lowest in France (45.9%). Further information on details of the procedure and the assessment of mental disorders can be found in the eMethods in the Supplement. A human subjects review board or ethics committee approved the survey protocol in each country (eTable 2 in the Supplement), and all respondents gave informed consent; the mode of consent (written vs oral) varied by survey.

#### Measures

**Psychotic Experiences**  
The Composite International Diagnostic Interview Psychosis Module included questions about 6 PE types—2 related to hallucinatory experiences and 4 related to delusional experiences. We excluded PEs experienced while dreaming, half-asleep, or under the influence of alcohol or drugs (eTable 3A and B in the Supplement). In this article, we present estimates of STBs for “Any PEs” only (ie, not individual types of PEs). In addition, we included 2 key PE variables: (1) number of PE types; and (2) an annualized frequency metric based on the frequency of PE episodes (ie, the count of PE occurrences per year). We derived the latter by dividing the total number of PE episodes by the time since onset of the first PE (age at interview minus age at onset plus 1 in order to avoid zero as a denominator). Age at onset of PEs was also assessed.

**Suicidality**  
Lifetime STBs were assessed using the Composite International Diagnostic Interview Suicidality Module.\(^1\) Separate questions were asked about the lifetime occurrence of suicidal ideation (“Have you ever seriously thought about committing suicide?”), suicide plans (“Have you ever made a plan for committing suicide?”), and suicide attempt (“Have you ever...
Psychotic Experiences and Suicidal Thoughts and Behaviors

Table 1. Lifetime Prevalence of Suicidal Ideation, Plans, and Attempts

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Ideation</th>
<th>Plans</th>
<th>Attempts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No./Total No. (%)</td>
<td>SE</td>
<td>No./Total No. (%)</td>
</tr>
<tr>
<td>STB prevalence</td>
<td>5106/33370 (9.2)</td>
<td>0.2</td>
<td>2000/33370 (3.1)</td>
</tr>
<tr>
<td>PE status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No PE</td>
<td>4165/30882 (8.0)</td>
<td>0.2</td>
<td>1583/30882 (2.6)</td>
</tr>
<tr>
<td>Any PE</td>
<td>941/2488 (38.5)</td>
<td>1.3</td>
<td>417/2488 (10.8)</td>
</tr>
<tr>
<td>No. of PE types (in those with PEs)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exactly 1 PE type</td>
<td>571/1706 (33.8)</td>
<td>1.4</td>
<td>236/1706 (13.8)</td>
</tr>
<tr>
<td>Exactly 2 PE types</td>
<td>247/566 (35.4)</td>
<td>3.4</td>
<td>111/566 (12.8)</td>
</tr>
<tr>
<td>≥3 PE types</td>
<td>123/216 (57.5)</td>
<td>4.9</td>
<td>70/216 (28.8)</td>
</tr>
<tr>
<td>PE annualized frequency metric (in those with PEs)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤0.3 Episodes/y</td>
<td>425/1259 (33.7)</td>
<td>1.9</td>
<td>183/1259 (9.6)</td>
</tr>
<tr>
<td>&gt;0.3 Episodes/y</td>
<td>516/1229 (33.7)</td>
<td>1.8</td>
<td>234/1229 (12.2)</td>
</tr>
</tbody>
</table>

Abbreviations: PE, psychotic experience; STB, suicidal thoughts and behaviors.

Results

Prevalence of STBs

The lifetime prevalence (SE) of suicidal ideation, plans, and attempts in all respondents was 9.2% (0.2), 3.1% (0.1), and 2.8% (0.1), respectively (Table 1). Among 5106 individuals with suicidal ideation, 2000 (33.6%; SE, 0.9) reported a suicide plan. Among the subset of 2000 individuals with suicidal ideation with a plan, the prevalence of suicide attempts was 55.5% (SE, 1.5). Among the subset of 3106 individuals with suicidal ideation without a plan, the prevalence of suicide attempts was 17.0% (SE, 0.9). (The proportions for the nested suicide outcomes reflect different denominators; eTable 4 in the Supplement.) The lifetime prevalence of STBs was substantially higher among those with PEs compared with those without PEs (Table 1). Specifically, among respondents with PEs, the prevalence (SE) of suicidal ideation, plans, and attempts was 17.0% (SE, 0.9), 10.8% (0.7), and 10.2% (0.7), respectively, compared with 8.0% (0.2), 2.6% (0.1), and 2.3% (0.1) for respondents without PEs.
Associations Between Lifetime PEs and Subsequent Onset of STBs

Compared with those without PEs, those with any PEs had 3-fold the odds of a subsequent first onset of each STB outcome after adjusting for demographic factors (Table 2), with adjusted ORs for suicidal ideation, plans, and attempts of 3.0 (95% CI, 2.6-3.6), 3.4 (95% CI, 2.8-4.1), and 3.1 (95% CI, 2.4-3.9), respectively. When adjusted for antecedent mental disorders, the pattern of associations remained significant though the effect sizes were attenuated.

Table 2. Associations Between Lifetime PEs and Subsequent Onset of Suicidal Ideation, Plans, and Attempts, With and Without Adjustment for Antecedent Mental Disorders

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ideation</td>
</tr>
<tr>
<td></td>
<td>Basic</td>
</tr>
<tr>
<td></td>
<td>Demographic</td>
</tr>
<tr>
<td></td>
<td>Adjustmenta</td>
</tr>
<tr>
<td>PE status</td>
<td></td>
</tr>
<tr>
<td>Any PE</td>
<td>3.0 (2.6-3.6)a</td>
</tr>
<tr>
<td>No. of PE types</td>
<td></td>
</tr>
<tr>
<td>Exactly 1 PE type</td>
<td>2.5 (2.0-3.1)a</td>
</tr>
<tr>
<td>Exactly 2 PE types</td>
<td>3.7 (2.7-4.9)a</td>
</tr>
<tr>
<td>≥3 PE types</td>
<td>7.1 (4.9-10.3)a</td>
</tr>
</tbody>
</table>

Joint significance of the PE type measures

χ² | 256.2 | 112.9 | 203.1 | 63.7 | 137.5 | 30.5 |

P value | <.001 | <.001 | <.001 | <.001 | <.001 | <.001 |

Difference in the ORs of the PE type measures

χ² | 24.3 | 14.7 | 32.4 | 15.0 | 26.0 | 7.6 |

P value | <.001 | <.001 | <.001 | <.001 | <.001 | <.001 |

Test for linear trend

χ² | 15.0 | 13.2 | 20.6 | 14.3 | 24.7 | 14.6 |

P value | <.001 | <.001 | <.001 | <.001 | <.001 | <.001 |

PE frequency metric

χ² | >0.3 Episodes/y | 3.5 (2.8-4.3)a | 2.4 (2.0-3.0)a | 3.8 (2.9-5.1)a | 2.3 (1.7-3.0)a | 3.0 (2.3-4.1)a | 1.8 (1.3-2.5)a |

P value | <.001 | <.001 | <.001 | <.001 | <.001 | <.001 |

Abbreviations: OR, odds ratio; PE, psychotic experience; STB, suicidal thoughts and behaviors.

a Psychotic experience (any PE, number of PE type, and frequency metric) was used as a predictor of STB outcomes in separate discrete-time survival models. These models control for age cohorts, sex, person-year dummies, and country.

b These models additionally control for 21 other antecedent mental disorders.

When we restricted the analysis to the subset with suicidal ideation, the associations of any PEs with suicide plans and suicide attempts were not significant, indicating that PEs are associated with increased odds of suicidal ideation but not with an increased odds of planning or attempting suicide among those reporting suicide ideation (eTable 5 in the Supplement). As a post hoc analysis, we also repeated the analysis stratified by mental disorders (yes/no). While the 95% CIs were wider in the subgroup with no mental disorders, the general pattern of findings persisted (eTable 6 in the Supplement).

Associations Between Lifetime PEs and Subsequent Onset of STBs Across 4 Life Course Stages

Table 3 shows the associations between PEs and subsequent onset of STBs across 4 life course stages. In the basic demographic adjustment models, we found strong and significant associations between occurrence of PEs and subsequent onset of STBs in all 4 life course stages (childhood, adolescence, early adulthood, and later adulthood). The effect sizes were significantly higher in childhood compared with other age groups (ideation: χ² = 14.7; P < .001; plans: χ² = 17.6; P < .001; and attempts: χ² = 8.8; P = .003). The ORs for suicidal ideation, plans, and attempts in childhood were 4.0 (95% CI, 2.3-6.8), 7.8 (95% CI, 3.4-17.9), and 5.4 (95% CI, 2.6-11.3), respectively. When adjusted for antecedent mental disorders, the pattern of associations remained significant though the effect sizes were attenuated.
PARPs Between PEs and STBs

The overall PARPs for suicidal ideation, plans, and attempts ranged between 8.4% and 11.0% (Table 4) in the basic demographic adjustment models. After adjustments for antecedent mental disorders, the overall PARPs were smaller, ranging from 4.8% to 5.7%. When examined across the life course, compared with older age groups, children 12 years and younger consistently had the highest PARPs (9.0%, 20.0%, and 11.1% for suicidal ideation, plans, and attempts, respectively) after adjustment for antecedent mental disorders.

Discussion

The results reported here are based on, to our knowledge, the largest and most detailed study of PEs and STBs reported to date. We found that community respondents who reported PEs had 2-fold increased odds of subsequent suicidal ideation, plans, and attempts after adjustment for antecedent mental disorders. These estimates are broadly consistent with several longitudinal studies\(^1,5,13,20\) but slightly lower than the pooled estimate from a 2016 meta-analysis.\(^1\) We also found a dose-response relationship between (1) higher numbers of PE types (in keeping with previous literature)\(^2,5\) and (2) higher annualized PE frequency with subsequent STBs. Additionally, these results shed new light on 4 issues. First, the association between PEs and STBs persisted after adjustment for antecedent mental disorders. Second, among the subset of respondents reporting suicidal ideation, PEs did not contribute significantly to increased odds of subsequent suicide plans or attempts. Third, the association between PEs and STBs was most prominent in children 12 years and younger. Fourth, PEs accounted for an appreciable proportion of STBs (9%-20%) during childhood, even when adjusted for antecedent mental disorders. We discuss each of these in turn.

First, although the association between PEs and STBs was attenuated after adjustment for 21 antecedent mental disorders, appreciable ORs (at least 2-fold) were still found between PEs and STBs. These finding are consistent with previous studies\(^1,3,21\) and lend weight to the hypothesis that the experience of PEs, even in the absence of mental disorders, may be sufficient to influence the subsequent onset of STBs. This is an important finding from a clinical point of view because it suggests that PEs may be a predictor of subsequent STBs even in individuals who do not meet criteria for mental disorders. In keeping with a 2017 commentary,\(^22\) we do not propose that the presence of isolated
PEs is sufficient to identify individuals with an ultrahigh risk of later transition to psychotic disorder; however, these individuals do have an increased risk of a range of other adverse outcomes, including STBs. Psychotic experiences and suicidality may share common risk factors (eg, traumatic life events or family history). Previous research found that the association between PEs and STBs persisted after adjusting for trauma and experiencing harm.\textsuperscript{3,4} We hypothesize that as PEs are associated with both psychological distress\textsuperscript{23} and disability,\textsuperscript{24,25} these factors may be sufficient to contribute to the emergence of subsequent STBs. However, we note that it is conceivable that PEs and STBs may both emerge during a prodromal phase of a later mental disorder (ie, a disorder with an age at onset after prior STBs). Although this analysis is beyond the scope of the current article, such research could further reinforce the clinical utility of routine monitoring of PEs in at-risk samples. Future studies may wish to include measures of disorganized speech, which is a clinical feature of psychotic disorder not routinely included in PE assessment.

Second, we demonstrated, to our knowledge for the first time, that although PEs were associated with an overall increase in STBs, among those with suicidal ideation, they did not make an additional contribution to the subsequent transition to suicide plans or planned/unplanned attempts. In other words, while those with PEs had an increased odds of each of the 3 STB outcomes (ie, suicidal ideation, suicide plans, and suicide attempts), our findings suggest that the presence of PEs did not alter the odds of transition from suicidal ideation to planned or unplanned attempts. This general pattern is consistent with previous research that explored the associations of mental disorders and these nested STB outcomes.\textsuperscript{11} However, the results are in contrast to DeVylder et al\textsuperscript{16} who found that respondents with PEs and suicidal ideation had more than 3-fold increased risk of attempting suicide. This discrepancy may reflect differences in methods related to the use of temporal ordering between the variables of interest.

Third, we found that PEs were associated with the subsequent onset of STBs in each of the 4 life course stages and that this pattern of associations persisted after adjustment for antecedent mental disorders. Mindful that PEs have a wide age-at-onset distribution (median [interquartile range], 26 [17-41] years),\textsuperscript{26} our findings support the hypothesis that PEs are associated with an increased odds of subsequent STBs regardless of age. However, we confirmed that the association between PEs and STBs was indeed more prominent in childhood, consistent with previous findings based on longitudinal studies.\textsuperscript{5,6,20,27} While our study was based on adult respondents (18 years and older), it is reassuring to note that the strong association between childhood-onset PEs and STBs has been confirmed in both broad cross-sectionally ascertained samples, like the WMH, and prospectively studied adolescent cohorts. Future studies may wish to explore biological and psychosocial factors that could explain why the association between PEs and subsequent STBs is stronger in young children compared with other age groups (eg, a differential sensitivity to stress).\textsuperscript{28,29}

Finally, we showed that after adjustment for antecedent mental disorders, the overall PARP estimates (between 4.8% and 5.7%) were smaller than previously reported.\textsuperscript{6,16} However, in children, the adjusted PARPs (between 9% and 20%) were similar to previously reported PARPs. We recommend caution when interpreting PARPs—these estimates assume causality between the variables of interest.\textsuperscript{19} These findings lend weight to the recommendation by Kelleher et al\textsuperscript{16} that clinicians should include PEs when assessing risk of STBs in young people and that future clinical and epidemiologic studies of STBs should include PE-related items in their risk factor battery.

**Limitations**

The current study has several strengths (large sample size, range of countries, uniform methods for data collection, temporally ordered variables, etc). However, it is important to note the study limitations. First, although we excluded people who were screened positive for possible psychotic disorders, the WMH surveys were administered by lay interviewers, and clinical validation of self-reported diagnoses of psychosis or mania was not available. Second, we also used retrospective reports of age at onset of the PEs, STBs, and mental disorders; although rigorously obtained,\textsuperscript{30} this is subject to some level of recall bias. However, we note that 5 prospective studies have confirmed the association between PEs and subsequent STBs.\textsuperscript{5,6,20,27,31} Third, the surveys were cross-sectional, and without additional follow-up, we were unable to examine the association between PEs and completed suicide. We are aware of 2 prospective community-based studies that explored this question, but both lacked sufficient power (ie, small number of completed suicides) to confidently estimate the influence of PEs on this outcome.\textsuperscript{70,32} Fourth, it will be of interest to explore if particular types of PEs (eg, hallucinations or delusions) are differentially associated with STBs in future analyses.

**Conclusions**

We found that PEs were independently associated with subsequent STBs regardless of antecedent mental disorders. There were significant dose-dependent relationships between both number of PE types and annualized frequency of PEs with subsequent STBs. The association was found at all ages, with a stronger effect at younger ages, and were associated with appreciable PARPs. From a public health perspective, we speculate that the inclusion of PE items in routine screening tools could improve the prediction of suicide risk. Our study lends additional weight to the call for the routine inclusion of PE items when assessing STBs in both research and clinical settings.
Author Contributions: Dr Kessler had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Bromet, Lim, Al-Hamzawi, Haro, Karam, Mneimneh, Xavier, Kessler, McGrath.


Critical revision of the manuscript for important intellectual content: Bromet, Saha, Lim, Aguilar-Gaxiola, Al-Hamzawi, Alonso, Borges, Brauffaerts, Degenhardt, de Girolamo, de Jonge, Florescu, Gureje, Haro, He, Hu, Kovess-Masyf, Lee, Lepe, Mneimneh, Navarro-Mateu, Ogajobi, Posada-Villa, Sampson, Scott, Stagnaro, Viana, Xavier, Kessler, McGrath.

Statistical analysis: Saha, Lim, Sampson, Stagnaro, Kessler, McGrath.

Drafting of the manuscript: Bromet, Nock, Saha, Lim, McGrath.

Administrative, technical, or material support: Aguilar-Gaxiola, Brauffaerts, de Girolamo, He, Hu, Lepe, Mneimneh, Posada-Villa.

Supervision: Aguilar-Gaxiola, de Girolamo, Karam, Kovess-Masyf, Navarro-Mateu, Sampeou, McGrath.

Funding/Support: The World Health Organization World Mental Health Survey Initiative is supported by the National Institute of Mental Health (grant R01 MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (grants R13-MH066849, R01-MH069684, and R01 DA016558), the Fogarty International Center (grant FICRA R3-TW00468T), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical, AstraZeneca, and Bristol-Myers Squibb. The Argentina survey—Estudio Argentino de Epilepsia en Salud Mental—is supported by a grant from the Argentinean Ministry of Health (Ministerio de Salud de la Nación). The Colombian National Study of Mental Health is supported by the Ministry of Social Welfare. The European Study of the Epidemiology of Mental Disorders project is funded by the European Commission (contractsQLGS-1999-01042, SANCO 2004123, and EAHC 20080082), the Centre for Mental Health Research, University of Queensland, Brisbane, Queensland, Australia (McGrath); Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia (McGrath); National Centre for Register-Based Research, Aarhus School of Business and Social Sciences, Aarhus University, Aarhus, Denmark (McGrath).

Conflict of Interest Disclosures: In the past 3 years, Dr Kessler has received support for his epidemiological studies from Sanofi Aventis, was a consultant for Johnson & Johnson Wellness and Prevention, and served on an advisory board for the Johnson & Johnson Services Lake Nona Life Project. Kessler is a co-owner of DataStat, a market research firm that carries out health care research. No other disclosures were reported.

Funding/Support: The World Health Organization World Mental Health Survey Initiative is supported by the National Institute of Mental Health (grant R01 MH070884), the John D. and Catherine T. MacArthur Foundation; the Pfizer Foundation, the US Public Health Service (grants R13-MH066849, R01-MH069684, and R01 DA016558), the Fogarty International Center (grant FICRA R3-TW00468T), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical, AstraZeneca, and Bristol-Myers Squibb. The Argentina survey—Estudio Argentino de Epilepsia en Salud Mental—is supported by a grant from the Argentinean Ministry of Health (Ministerio de Salud de la Nación). The Colombian National Study of Mental Health is supported by the Ministry of Social Welfare. The European Study of the Epidemiology of Mental Disorders project is funded by the European Commission (contractsQLGS-1999-01042, SANCO 2004123, and EAHC 20080082), the Centre for Mental Health Research, University of Queensland, Brisbane, Queensland, Australia (McGrath); Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia (McGrath); National Centre for Register-Based Research, Aarhus School of Business and Social Sciences, Aarhus University, Aarhus, Denmark (McGrath).

Conflict of Interest Disclosures: In the past 3 years, Dr Kessler has received support for his epidemiological studies from Sanofi Aventis, was a consultant for Johnson & Johnson Wellness and Prevention, and served on an advisory board for the Johnson & Johnson Services Lake Nona Life Project. Kessler is a co-owner of DataStat, a market research firm that carries out health care research. No other disclosures were reported.

Funding/Support: The World Health Organization World Mental Health Survey Initiative is supported by the National Institute of Mental Health (grant R01 MH070884), the John D. and Catherine T. MacArthur Foundation; the Pfizer Foundation, the US Public Health Service (grants R13-MH066849, R01-MH069684, and R01 DA016558), the Fogarty International Center (grant FICRA R3-TW00468T), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical, AstraZeneca, and Bristol-Myers Squibb. The Argentina survey—Estudio Argentino de Epilepsia en Salud Mental—is supported by a grant from the Argentinean Ministry of Health (Ministerio de Salud de la Nación). The Colombian National Study of Mental Health is supported by the Ministry of Social Welfare. The European Study of the Epidemiology of Mental Disorders project is funded by the European Commission (contracts QLGS-1999-01042, SANCO 2004123, and EAHC 20080082), the Centre for Mental Health Research, University of Queensland, Brisbane, Queensland, Australia (McGrath); Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia (McGrath); National Centre for Register-Based Research, Aarhus School of Business and Social Sciences, Aarhus University, Aarhus, Denmark (McGrath).

Conflict of Interest Disclosures: In the past 3 years, Dr Kessler has received support for his epidemiological studies from Sanofi Aventis, was a consultant for Johnson & Johnson Wellness and Prevention, and served on an advisory board for the Johnson & Johnson Services Lake Nona Life Project. Kessler is a co-owner of DataStat, a market research firm that carries out health care research. No other disclosures were reported.

Funding/Support: The World Health Organization World Mental Health Survey Initiative is supported by the National Institute of Mental Health (grant R01 MH070884), the John D. and Catherine T. MacArthur Foundation; the Pfizer Foundation, the US Public Health Service (grants R13-MH066849, R01-MH069684, and R01 DA016558), the Fogarty International Center (grant FICRA R3-TW00468T), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical, AstraZeneca, and Bristol-Myers Squibb. The Argentina survey—Estudio Argentino de Epilepsia en Salud Mental—is supported by a grant from the Argentinean Ministry of Health (Ministerio de Salud de la Nación). The Colombian National Study of Mental Health is supported by the Ministry of Social Welfare. The European Study of the Epidemiology of Mental Disorders project is funded by the European Commission (contracts QLGS-1999-01042, SANCO 2004123, and EAHC 20080082), the Centre for Mental Health Research, University of Queensland, Brisbane, Queensland, Australia (McGrath); Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia (McGrath); National Centre for Register-Based Research, Aarhus School of Business and Social Sciences, Aarhus University, Aarhus, Denmark (McGrath).

Conflict of Interest Disclosures: In the past 3 years, Dr Kessler has received support for his epidemiological studies from Sanofi Aventis, was a consultant for Johnson & Johnson Wellness and Prevention, and served on an advisory board for the Johnson & Johnson Services Lake Nona Life Project. Kessler is a co-owner of DataStat, a market research firm that carries out health care research. No other disclosures were reported.

Funding/Support: The World Health Organization World Mental Health Survey Initiative is supported by the National Institute of Mental Health (grant R01 MH070884), the John D. and Catherine T. MacArthur Foundation; the Pfizer Foundation, the US Public Health Service (grants R13-MH066849, R01-MH069684, and R01 DA016558), the Fogarty International Center (grant FICRA R3-TW00468T), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical, AstraZeneca, and Bristol-Myers Squibb. The Argentina survey—Estudio Argentino de Epilepsia en Salud Mental—is supported by a grant from the Argentinean Ministry of Health (Ministerio de Salud de la Nación). The Colombian National Study of Mental Health is supported by the Ministry of Social Welfare. The European Study of the Epidemiology of Mental Disorders project is funded by the European Commission (contracts QLGS-1999-01042, SANCO 2004123, and EAHC 20080082), the Centre for Mental Health Research, University of Queensland, Brisbane, Queensland, Australia (McGrath); Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia (McGrath); National Centre for Register-Based Research, Aarhus School of Business and Social Sciences, Aarhus University, Aarhus, Denmark (McGrath).

Conflict of Interest Disclosures: In the past 3 years, Dr Kessler has received support for his epidemiological studies from Sanofi Aventis, was a consultant for Johnson & Johnson Wellness and Prevention, and served on an advisory board for the Johnson & Johnson Services Lake Nona Life Project. Kessler is a co-owner of DataStat, a market research firm that carries out health care research. No other disclosures were reported.

Funding/Support: The World Health Organization World Mental Health Survey Initiative is supported by the National Institute of Mental Health (grant R01 MH070884), the John D. and Catherine T. MacArthur Foundation; the Pfizer Foundation, the US Public Health Service (grants R13-MH066849, R01-MH069684, and R01 DA016558), the Fogarty International Center (grant FICRA R3-TW00468T), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical, AstraZeneca, and Bristol-Myers Squibb. The Argentina survey—Estudio Argentino de Epilepsia en Salud Mental—is supported by a grant from the Argentinean Ministry of Health (Ministerio de Salud de la Nación). The Colombian National Study of Mental Health is supported by the Ministry of Social Welfare. The European Study of the Epidemiology of Mental Disorders project is funded by the European Commission (contracts QLGS-1999-01042, SANCO 2004123, and EAHC 20080082), the Centre for Mental Health Research, University of Queensland, Brisbane, Queensland, Australia (McGrath); Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia (McGrath); National Centre for Register-Based Research, Aarhus School of Business and Social Sciences, Aarhus University, Aarhus, Denmark (McGrath).
Psychotic Experiences and Suicidal Thoughts and Behaviors

Administration, the Robert Wood Johnson Foundation (grant 04-4708), and the John W. Alden Trust. Dr. McGinty received John E. Fogarty Fellowship APP1056929 from the National Health and Mental Health Research Council and Nils Bohr Professorship from the Danish National Research Foundation.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: The World Health Organization World Mental Health Survey collaborators are Sergio Aguilar-Gaxiola, MD, PhD (Center for Reducing Health Disparities, University of California-Davis Health System, Sacramento); Ali Al-Hamzawi, MD (College of Medicine, Al-Qadiya University, Diwanyja Governorate, Iraq); Mohammed Saleh Al-Kaisy, MD ( Ibn Seena Teaching Hospital, Alkhdirha, Baghdad, Iraq); Jordi Alonso, MD, PhD (Health Services Research Unit, Hospital del Mar Medical Research Institute, Barcelona, Spain); Laura Helena Andrade, MD, PhD (Section of Psychiatry, Hokkaido University Hospital, Sapporo, Japan); Evelyne J. Bremot, PhD (Department of Psychiatry, Stony Brook University School of Medicine, Stony Brook, New York); Ronny Bruffaerts, PhD (University Institute of Psychiatrisch Centrum, Katholieke Universiteit Leuven, Campus Gasthuisberg, Leuven, Belgium); Brendan Bunting, PhD (School of Psychology, Ulster University, Londonderry, United Kingdom); Jose Miguel Caldas de Almeida, MD, PhD (Chronic Diseases Research Center, Department of Mental Health, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal); Graca Cardoso, MD, PhD (Department of Mental Health, Faculdades de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal); Sonnath Chatterji, MD (Department of Information, Evidence and Research, World Health Organization, Geneva, Switzerland); Alfredo H. Cia, MD (Department of Psychiatric Services, Integrated Centers, Buenos Aires, Argentina); Louisa Degenhardt, PhD (National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia); Koen Demyttenaere, MD, PhD (Department of Psychiatry, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium); John Fayyad, MD (Institute for Development, Research, Advocacy and Applied Care, Beirut, Lebanon); Silvia Florescu, MD, PhD (National School of Public Health and Mental Health, School of Public Health, The University of Tokyo, Tokyo, Japan); Elie G. Karam, MD (Department of Psychiatry and Clinical Psychology, Faculty of Medicine, St George Hospital University Medical Center, Balamban University, Beirut, Lebanon); Norito Kawakami, MD, DMSc (Department of Mental Health, School of Public Health, The University of Tokyo, Tokyo, Japan); Ronald C. Kessler, PhD (Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts); Andrej Kiejna, MD, PhD (Wrocław Medical University, University of Lower Silesia, Wrocław, Poland); Viviane Koeves-Masfety, MD, PhD (École des Hautes Études en Santé Publique, Paris Descartes University, Paris, France); Sing Lee, MBBS (Department of Psychiatry, Chinese University of Hong Kong, Hong Kong); Jean-Pierre Lepine, MD (Hôpital Lariboisière-Fernand Widal, Assistance Publique Hôpitaux de Paris, Université Paris Descartes-Paris Diderot, INSERM UMR S1144, Paris, France); Daphna Levinson, PhD (Mental Health Services, Ministry of Health, Jerusalem, Israel); John McGrath, MD, PhD (Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Woolooware, Queensland, Australia); Maria Elena Medina-Mora, PhD (National Institute of Psychiatry Ramón de la Fuente, Mexico City, Mexico); Jack Mosalewicz, PhD (Institute of Psychiatry and Neurology, Warsaw, Poland); Fernando Navarro-Mateu, MD, PhD (Unidad de Docencia, Investigación y Formación en Salud Mental, Subdirección General de Planeación, Innovación y Cronicidad, Servicio Murciano de Salud, Instituto Murciano de Investigación Biomatérica-Arrixaca, Centro de Investigación Biómédica en Red de Epidemiología y Salud Pública-Murcia, Murcia, Spain); Beth-Ellen Pennell, MA (Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor); Marina Piazza, MPH, ScD (National Institute of Health, Lima, Peru); Jose Posada-Villa, MD (Collegio Mayor de Cundinamarca University, Faculty of Social Sciences, Bogota, Colombia); Kate M. Scott, PhD (Department of Psychological Medicine, University of Otago, Dunedin, Otago, New Zealand); Tim Slade, PhD (National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia); Juan Carlos Stagnaro, MD, PhD (Departamento de Salud Mental y Salud Mental, Facultad de Medicina, Universidad de Buenos Aires, Argentina); Dan J. Stein, FRCP, PhD (Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, Republic of South Africa); Margreet ten Have, PhD (Trimbos-Instituut, Nederlands Instituut van Mental Health and Addiction, Utrecht, the Netherlands); Yolanda Torres, MPH, DraHC (Center for Excellence on Research in Mental Health, CES University, Medellin, Colombia); Maria Carmen Viana, MD, PhD (Department of Social Medicine, Federal University of Espirito Santo, Vitoria, Brazil); Harvey Whiteford, MBBS, PhD (School of Public Health, University of Queensland, Brisbane, Queensland, Australia); David R. Williams, MPH, PhD (Department of Society, Human Development, and Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts); and Bogdan Wojtyniak, ScD (Centre of Monitoring and Analyses of Population Health, National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland). A complete list of all within-country and cross-national WMH publications can be found at http://www.hcp.med.harvard.edu/wmh/.

Disclaimer: The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of the World Health Organization, other sponsoring organizations, agencies, or governments.

Additional Contributions: We thank the staff of the World Mental Health Data Collection and Data Analysis Coordinating Centres for assistance with instrumentation, fieldwork, and consultation on data analysis.

REFERENCES


